Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Asthma is a complex respiratory disease that varies in severity and response to treatment. Several asthma phenotypes with unique clinical and inflammatory characteristics have been identified. Endotypes, based on distinct molecular profiles, help to further elucidate the heterogeneity within asthma. Type 2 inflammation, involving both the innate (type 2 innate lymphoid cell) and adaptive (T-helper type 2 cells) immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease (e.g.chronic rhinosinusitis with nasal polyps, allergic rhinitis and atopic dermatitis). Type 2 inflammation is characterised by upregulation of the type 2 cytokines interleukin (IL)-4, IL-5 and IL-13, IgE-mediated release of immune mediators and dysfunction of epithelial or epidermal barriers. Targeting these key proximal type 2 cytokines has shown efficacy in recent studies adopting a personalised approach to treatment using targeted biologics. Elevated levels of biomarkers downstream of type 2 cytokines, including fractional exhaled nitric oxide, serum IgE and blood and sputum eosinophils, have been linked to mechanisms involved in type 2 inflammation. They have the potential to aid diagnosis, and to predict and monitor response to treatment. The objective of this review is to summarise the current understanding of the biology of type 2 inflammation in asthma, examine its influence on type 2 inflammatory comorbidities, and discuss how type 2 inflammatory biomarkers can be harnessed to further personalise treatments in the age of biologic medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729 · cited 1×
“Similarly, >80% of patients with asthma have AR, and up to 40% of patients with AR have comorbid asthma [56, 57].”
Self-citationDweik, R. A., Boggs, P. B., Erzurum, S. C., Irvin, C. G., Leigh, M. W., Lundberg, J. O., Olin, A.-C., Plummer, A. L., & Taylor, D. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.9120-11st · Cited by 2,539
Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940 · cited 2×
“TGF-β antagonists (soluble TGF β R-Fc) decrease IL-13-induced lung collagen production in mice [46].”
Targeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557 · cited 1×
“Similarly, >80% of patients with asthma have AR, and up to 40% of patients with AR have comorbid asthma [56, 57].”
Commonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493 · cited 1×
“The overlapping functions of IL-4 and IL-13 may be due to receptor and cytokine expression patterns, because both cytokines signal through two potentially heterodimeric receptors with a shared receptor moiety, the IL-4R α chain [27].”
Comorbidities and the impact of atopic dermatitis
Silverberg, J. I. (2019) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2019.04.020 · Cited by 431
Eifan, A. O., & Durham, S. R. (2016) · Clinical & Experimental Allergy · doi:10.1111/cea.12780 · Cited by 379
IL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent
Kaviratne, M., Hesse, M., Leusink, M., Cheever, A. W., Davies, S. J., McKerrow, J. H., Wakefield, L. M., Letterio, J. J., & Wynn, T. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4020 · Cited by 370 · cited 1×
“There is also evidence that IL-13 induces sub-epithelial fibrosis through direct effects on fibroblast proliferation and collagen production, both dependent on [48] and independent of [49] TGF-β .”
Interleukin-5 in the Pathophysiology of Severe Asthma.
Pelaia, C., Paoletti, G., Puggioni, F., Racca, F., Pelaia, G., Canonica, G. W., & Heffler, E. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01514 · Cited by 337 · cited 1×
“IL-5 has also been implicated in epithelial desquamation and airway remodelling [42].”
Steelant, B., Farré, R., Wawrzyniak, P., Belmans, J., Dekimpe, E., Vanheel, H., Van Gerven, L., Kortekaas Krohn, I., Bullens, D. M. A., Ceuppens, J. L., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.050 · Cited by 336
Overview on the pathomechanisms of allergic rhinitis
Pawankar, R., Mori, S., Ozu, C., & Kimura, S. (2011) · Asia Pacific Allergy · doi:10.5415/apallergy.2011.1.3.157 · Cited by 280 · cited 1×
“The inflammatory response in the nasal mucosa in AR includes an early IgE-mediated and a late-phase response that includes recruitment of eosinophils and basophils, and release of type 2 cytokines including IL-4, IL-5 and IL-13 [66].”
Allergic Bronchopulmonary Aspergillosis
Greenberger, P. A., Bush, R. K., Demain, J. G., Luong, A., Slavin, R. G., & Knutsen, A. P. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.08.007 · Cited by 167 · cited 1×
“…applications of this biomarker are to estimate the optimal dosage of the anti-IgE antibody omalizumab [81] for add-on treatment in severe allergic asthma, and to support screening for allergic bronchopulmonary aspergillosis, a condition that is often accompanied by very high serum total IgE [82].”
Cited by
The role of NLRP3 inflammasome in type 2 inflammation related diseases
Xu, S., Wang, D., Tan, L., & Lu, J. (2024) · Autoimmunity · doi:10.1080/08916934.2024.2310269 · Cited by 43
Metadata
- Authors
- Busse, W. W., Kraft, M., Rabe, K. F., Deniz, Y., Rowe, P. J., Ruddy, M., & Castro, M.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2021-02-04
- Volume
- 58
- Issue
- 2
- Pages
- 2003393
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W3128930788
- Cited by
- 164
- References
- 14
- FWCI
- 13.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.